Results from phase 1 Primary endpoint was the number of heroin positive urine samples. Urine was tested on 6-Mono-AcetylMorphine (metabolite of heroin) and 6-Acetyl-Codein (by-product of illegal heroin production). The non-inferiority margin was pre-defined at 10%. Overall the slight differences in positive urines were within the predefined non-inferiority margin and showed a negative correlation with the substitution dose. The number of adverse events showed no difference between the substances.
Results from phase 2 There was a reduction of hyperhidrosis on SROM, both in frequency and severity (p=.0001). QTc was lower on SROM by approx. 10msec. Craving for heroin declined over the 25 weeks. also dysthymic symptoms in SCL-27. Satisfaction with SROM treatment was high. The average daily dose of SROM (±SD) after stabilization at the end of week 1 was 777.14mg ±257.33mg. The dose stayed stable during the 25 weeks.
Conclusion
The results showing no inferiority of SROM were sufficient for an official registration of SROM** for the indication of OST in opioid dependent patients and SROM is since May 2013 available, for substitution, also in office-based treatment by general practitioners.
Introduction

History of opioid substitution treatment (OST)
The British doctor Francis E. Anstie suggested in 1871 the long term prescription of opioids for opioid dependent patients and thus was the first to advocate an opioid substitution treatment. In the early 20th century this form of treatment was widely applied, and the reasons were the same as today (stopping the use of street drugs, stabilization of the patients, and reduction of criminality). However, in the US this kind of treatment was stopped by 1923 as a consequence of stricter drug control, which was finally imposed also internationally (only the UK resisted with their "British system"). In the "narcotic farm" Lexington, Kentucky, methadone was instituted in the management of detoxification already in 1948, but only in 1964 Dole & Nyswander could start their trials with methadone as a maintenance medication. Due to political reasons a number of constraints, how the substance should be used (indication, dosing, counselling, takehome doses, urine tests) were established. MMT was restricted to specialized clinics. These rules were written down in the Narcotic Addict Control Act (NATA), which is an amendment to the Controlled Substance Act (CSA). These laws are enforced by the Drug Enforcement Agency (DEA). The restrictions served as a model for regulations in many other countries.
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The Swiss situation
In Switzerland methadone maintenance treatment (MMT) was available since the 1970ies. However, according to the narcotic law physicians need a license by the medical authorities to prescribe MMT. Other restrictions (minimal age, treatment experience, maximal dose) were loosened over time. The license was never restricted to specialized centers, so office based treatment was always possible. MMT is also in Switzerland the gold standard for OST, but many patients complain about disabling extensive sweating and insufficient well-being . Additionally patients in MMT show a high comorbidity and medications needed to treat these conditions may add to the prolongation of QTc induced by methadone, thus raising the risk for cardiac arrhythmia. In the view of the street-heroin epidemic of the early 1990ies, when large groups of heroin user could not be reached by MMT, the authorities agreed to conduct trials with injected heroin (1994) (1995) (1996) . The positive trial results allowed a proper registration of diacetyl-morphine ("heroin") as a substitution medication (heroin-assisted treatment HAT), but HAT is only possible in specialized clinics with a number of further restrictions (minimal age, treatment history, mandatory psychosocial treatment, no take-home etc.). In 2000 sublingual buprenorphine got based on existing data and an already existing European registration a national registration as substitution medication. Buprenorphine is listed in Switzerland as a narcotic, so the same licensing as for methadone is applied. After the peak of the heroin epidemic in the early 1990ies more and more heroin users switched from i.v. to nasal and smoked applications. So the i.v.-program of the HAT was not suitable for them and the HAT centers started off-label prescriptions of slow release oral morphine (SROM). An additional reason was that morphine prescription is subject to less restriction than diacetyl-morphine (possible take-home of SROM). However, existing data on SROM in opioid substitution treatment (OST) were despite positive reports from neighboring Austria not sufficient for a registration as a 4 th substitution medication. That's why it was decided to conduct a study. 6-year follow-up. Eur Addict Res 2003 April; 9(2):73-9. -Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety 
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